Debio 4228-201: Study of Extended Release GnRH in Newly Diagnosed Locally Advanced or Metastatic Prostate Cancer
Condition: Prostate Cancer
Sponsor: Debiopharm International SA
Full Title
Protocol Debio 4228-201: A Phase 2, randomized, open-Label, dose-finding study of Debio 4228, an extended-release formulation of gonadotropin-releasing hormone antagonist in participants with locally advanced/metastatic prostate cancer
Study Treatment
Debio 4228 - a 12 week extended release gonadotropin-releasing hormone antagonist (GnRH)
Eligibility/Info
- Locally advanced or metastatic prostate cancer
- No prior androgen deprivation therapy (ADT) or ≤6 months of treatment with ADT
- Eligible for continuous ADT
Contact
For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: 631-675-5075.
